Top Page
Venus Concept
(NASDAQ:VERO)
Venus Concept (VERO) vs. SPDR S&P 500 ETF (SPY)
Venus Concept Business Overview & Revenue Model
Venus Concept Earnings Call Summary
Venus Concept Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.88M | 64.83M | 76.35M | 99.50M | 105.62M | 78.01M |
| Gross Profit | 37.89M | 44.31M | 52.17M | 65.97M | 74.09M | 51.39M |
| EBITDA | -45.42M | -36.04M | -26.11M | -35.28M | -13.04M | -68.49M |
| Net Income | -54.61M | -47.00M | -37.25M | -43.70M | -23.01M | -81.71M |
Balance Sheet | ||||||
| Total Assets | 61.62M | 68.18M | 93.65M | 125.38M | 157.37M | 160.53M |
| Cash, Cash Equivalents and Short-Term Investments | 5.93M | 4.27M | 5.40M | 11.57M | 30.88M | 34.30M |
| Total Debt | 32.67M | 43.03M | 79.70M | 83.77M | 77.87M | 79.60M |
| Total Liabilities | 58.49M | 65.35M | 107.10M | 116.64M | 115.78M | 116.76M |
| Stockholders Equity | 2.67M | 2.37M | -14.02M | 8.09M | 40.94M | 44.23M |
Cash Flow | ||||||
| Free Cash Flow | -20.75M | -11.19M | -12.97M | -27.32M | -20.28M | -28.94M |
| Operating Cash Flow | -20.45M | -11.07M | -12.86M | -26.98M | -19.77M | -28.65M |
| Investing Cash Flow | -294.00K | -123.00K | -116.00K | -336.00K | -552.00K | -2.39M |
| Financing Cash Flow | 22.19M | 10.06M | 6.80M | 8.01M | 16.82M | 49.67M |
Venus Concept Technical Analysis
Venus Concept Risk Analysis
Venus Concept Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $10.04M | 0.32 | 20.03% | ― | -99.28% | -46.16% | |
40 Underperform | $3.92M | -0.04 | -854.61% | ― | -12.39% | 44.61% | |
38 Underperform | $3.44M | -0.07 | -191.39% | ― | ― | 76.53% | |
38 Underperform | $3.49M | -0.28 | ― | ― | ― | ― | |
29 Underperform | $2.14M | -0.04 | -126.20% | ― | ― | 97.70% |
Venus Concept Corporate Events
Venus Concept Inc. is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive aesthetic and hair restoration solutions across over 60 countries.
Venus Concept’s latest earnings call presented a mixed sentiment, with positive developments such as the launch of Venus Nova and improvements in the balance sheet, overshadowed by significant challenges. The company is grappling with declining overall revenue, increased losses, and ongoing difficulties with the Venus Hair business, leaving the financial outlook uncertain.
On November 10, 2025, Venus Concept announced it received 510(k) clearance from the FDA to market Venus Nova, its new multi-application platform for non-invasive treatments. The announcement is part of the company’s strategic efforts to stabilize and grow its business amidst challenging market conditions. Despite a decline in total revenue for the third quarter of 2025, the company reported stabilization in its Energy Based Device revenues and executed significant debt-to-equity exchanges to strengthen its financial position. The company is also working to close the sale of its Venus Hair Business, facing challenges that have led to seeking court assistance.
The most recent analyst rating on (VERO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
On October 31, 2025, Venus Concept Inc. and its subsidiaries entered into a Consent Agreement with Madryn Health Partners, providing relief under a prior loan agreement by waiving certain liquidity requirements and allowing interest payments to be applied to the principal balance. Additionally, they amended a bridge loan agreement to extend its maturity date and waive liquidity requirements until November 30, 2025. The company also completed a Thirteenth Delayed Drawdown on October 28, 2025, securing $2,000,000 for general working capital purposes.
The most recent analyst rating on (VERO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
On September 30, 2025, Venus Concept Inc. completed a debt-to-equity exchange agreement with Madryn Health Partners, converting $11.48 million of subordinated convertible notes into 545,335 shares of Series Y preferred stock. This transaction reduced Venus Concept’s total debt by 24%, enhancing its financial position and supporting its strategic initiatives for long-term growth and profitability. The exchange agreement also involved amendments to existing loan agreements, providing additional financial flexibility and extending loan maturity dates.
The most recent analyst rating on (VERO) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
On September 19, 2025, Venus Concept Inc. secured a twelfth delayed drawdown of $2,000,000 under its Loan and Security Agreement with Madryn Health Partners, intended for general working capital. Additionally, the board approved transaction completion bonuses for executives Rajiv De Silva and Domenic Della Penna, contingent upon the successful completion of a strategic transaction involving a change of control.
The most recent analyst rating on (VERO) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
On August 31, 2025, Venus Concept Inc. and its subsidiaries entered into several agreements with Madryn Health Partners to address liquidity requirements and loan maturity dates. The Consent Agreement waived certain minimum liquidity requirements under the MSLP Loan Agreement through September 30, 2025, while the Nineteenth Bridge Loan Amendment extended the maturity date of the Bridge Loan to September 30, 2025. Additionally, the Notes Consent Agreement waived liquidity requirements under the 2025 Notes, also through September 30, 2025. These agreements are aimed at providing financial relief and operational flexibility to Venus Concept Inc.
The most recent analyst rating on (VERO) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
Venus Concept’s recent earnings call painted a mixed picture of their financial health. The company showcased strategic achievements, such as sequential growth and a significant business sale, yet also faced ongoing challenges with revenue and profitability. While positive steps towards financial improvement were evident, significant issues remain, including revenue declines and increased losses.
Venus Concept Inc. announced the completion of its eleventh delayed drawdown under a Loan and Security Agreement with Madryn Health Partners, amounting to $2,000,000, on August 21, 2025. This funding is intended for general working capital purposes, reflecting the company’s ongoing efforts to secure financial stability and support its operations in the competitive medical aesthetics industry.
The most recent analyst rating on (VERO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.